БЛОГ

Nov 25, 2020

Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid Tumors

Posted by in category: biotech/medical

Adagrasib demonstrated an acceptable safety profile and promising clinical activity in pretreated patients with non-small cell lung cancer, colorectal cancer, and other solid tumors with a KRAS G12C mutation.

0 comments

Comments are closed.

Tag cloud

aging AI Alzheimer's anti-aging Artificial Intelligence bioquantine bioquark biotech biotechnology bitcoin blockchain brain death cancer cryptocurrency culture Death existential risks extinction future futurism Google health healthspan humanity ideaxme immortality Interstellar Travel ira pastor Life extension lifespan longevity NASA Neuroscience politics reanima regenerage regeneration research risks singularity space sustainability technology transhumanism wellness

Categories